Latest News for: tshr
Edit
Ethyreal Bio Emerges from Stealth with $101 Million in Financing to Advance ETHY-001, a Potentially Best-in-Class Anti-TSHR Antibody for Thyroid Eye Disease and Graves’ Disease (Avoro Capital Advisors LLC)
Public Technologies 16 Jun 2026
Ethyreal's lead program, ETHY-001, is a monoclonal antibody designed to block autoantibody-mediated activation of the thyroid stimulating hormone receptor (TSHR), the shared pathogenic driver of Graves' disease (GD) and thyroid eye disease (TED).
- 1